The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes

Autoimmunity Reviews

Volumn 12, Issue 9, 2013, Pages 875-884

  Marx, Alexander ^a   Pfister, Frederick ^a   Schalke, Berthold ^b   Saruhan Direskeneli, Güher ^c   Melms, Arthur ^d   Ströbel, Philipp ^e  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c ISTANBUL UNIVERSITY   (Turkey)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

AIRE; Myoid cell; Thymic atrophy; Thymic hyperplasia; Thymitis; Thymoma

Indexed keywords

ANTIBODY; APRIL PROTEIN; AUTOANTIBODY; AUTOANTIGEN; AUTOIMMUNE REGULATOR PROTEIN; B CELL ACTIVATING FACTOR; CHOLINERGIC RECEPTOR; CXCL13 CHEMOKINE; INTERLEUKIN 17F; INTERLEUKIN 22; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 4; MUSK PROTEIN; PROTEIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; COMPARATIVE STUDY; DISEASE ASSOCIATION; EPITHELIUM CELL; GENETIC ASSOCIATION; GENETIC RISK; GERMINAL CENTER; HEREDITY; HETEROZYGOSITY LOSS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LYMPH FOLLICLE; MICROENVIRONMENT; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; PATHOGENESIS; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; THYMECTOMY; THYMOCYTE; THYMOMA; THYMUS;

ANIMALS; AUTOANTIBODIES; HUMANS; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; T-LYMPHOCYTES; THYMUS GLAND;

EID: 84879188812     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.03.007     Document Type: Review

References (147)

1. Farrugia M.E., Vincent A. Autoimmune mediated neuromuscular junction defects. Curr Opin Neurol 2010, 23:489-495.
2. Vincent A. Autoimmune channelopathies: well-established and emerging immunotherapy-responsive diseases of the peripheral and central nervous systems. J Clin Immunol 2010, 30(Suppl. 1):S97-S102.
3. Marx A., Willcox N., Leite M.I., Chuang W.Y., Schalke B., Nix W., et al. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 2010, 43:413-427.
4. Patrick J., Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973, 180:871-872.
5. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365-368.
6. Higuchi O., Hamuro J., Motomura M., Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011, 69:418-422.
7. Pevzner A., Schoser B., Peters K., Cosma N.C., Karakatsani A., Schalke B., et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012, 259:427-435.
8. Zhang B., Tzartos J.S., Belimezi M., Ragheb S., Bealmear B., Lewis R.A., et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012, 69:445-451.
9. Zisimopoulou P., Brenner T., Trakas N., Tzartos S.J. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 2013, 12:924-930. (this issue).
10. Gregersen P.K., Kosoy R., Lee A.T., Lamb J., Sussman J., McKee D., et al. Risk for myasthenia gravis maps to a (151) Pro-->Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann Neurol 2012, 72(6):927-935.
11. Drachman D.B. Myasthenia gravis. N Engl J Med 1994, 330:1797-1810.
12. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002, 2:797-804.
13. Cavalcante P., Bernasconi P., Mantegazza R. Autoimmune mechanisms in myasthenia gravis. Curr Opin Neurol 2012, 25:621-629.
14. Carr A.S., Cardwell C.R., McCarron P.O., McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010, 10:46.
15. Heldal A.T., Eide G.E., Gilhus N.E., Romi F. Geographical distribution of a seropositive myasthenia gravis population. Muscle Nerve 2012, 45:815-819.
16. Albuquerque E.X., Pereira E.F., Alkondon M., Rogers S.W. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009, 89:73-120.
17. Luo J., Lindstrom J. Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors. Autoimmunity 2012, 45:245-252.
18. Tzartos S.J., Lindstrom J.M. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci U S A 1980, 77:755-759.
19. Sanes J.R., Lichtman J.W. Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat Rev Neurosci 2001, 2:791-805.
20. Wakkach A., Poea S., Chastre E., Gespach C., Lecerf F., De La Porte S., et al. Establishment of a human thymic myoid cell line. Phenotypic and functional characteristics. Am J Pathol 1999, 155:1229-1240.
21. Schluep M., Willcox N., Vincent A., Dhoot G.K., Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann Neurol 1987, 22:212-222.
22. Fraterman S., Khurana T.S., Rubinstein N.A. Identification of acetylcholine receptor subunits differentially expressed in singly and multiply innervated fibers of extraocular muscles. Invest Ophthalmol Vis Sci 2006, 47:3828-3834.
23. Siara J., Rudel R., Marx A. Absence of acetylcholine-induced current in epithelial cells from thymus glands and thymomas of myasthenia gravis patients. Neurology 1991, 41:128-131.
24. Poea-Guyon S., Christadoss P., Le Panse R., Guyon T., De Baets M., Wakkach A., et al. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol 2005, 174:5941-5949.
25. Giraud M., Taubert R., Vandiedonck C., Ke X., Levi-Strauss M., Pagani F., et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007, 448:934-937.
26. Leite M.I., Jones M., Strobel P., Marx A., Gold R., Niks E., et al. Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 2007, 171:893-905.
27. Vincent A. Impact commentaries. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 2012, 83:237-238.
28. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008, 131:1940-1952.
29. Verschuuren J.J.G.M., Huijbers M.G., Plomp J.J., Niks E.H., Molenaar P.C., Martinez-Martinez P., et al. Pathophysiology of maysthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-like protein 4. Autoimmun Rev 2013, 12:918-923. (this issue).
30. Vincent A., Jacobson L., Shillito P. Response to human acetylcholine receptor alpha 138-199: determinant spreading initiates autoimmunity to self-antigen in rabbits. Immunol Lett 1994, 39:269-275.
31. Hill M., Beeson D., Moss P., Jacobson L., Bond A., Corlett L., et al. Early-onset myasthenia gravis: a recurring T-cell epitope in the adult-specific acetylcholine receptor epsilon subunit presented by the susceptibility allele HLA-DR52a. Ann Neurol 1999, 45:224-231.
32. Curnow J., Corlett L., Willcox N., Vincent A. Presentation by myoblasts of an epitope from endogenous acetylcholine receptor indicates a potential role in the spreading of the immune response. J Neuroimmunol 2001, 115:127-134.
33. Maclennan C.A., Vincent A., Marx A., Willcox N., Gilhus N.E., Newsom-Davis J., et al. Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis. J Neuroimmunol 2008, 201-202:28-32.
34. Wang H.B., Shi F.D., Li H., Chambers B.J., Link H., Ljunggren H.G. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 2001, 166:6430-6436.
35. Hohlfeld R., Toyka K.V., Heininger K., Grosse-Wilde H., Kalies I. Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature 1984, 310:244-246.
36. Nagvekar N., Moody A.M., Moss P., Roxanis I., Curnow J., Beeson D., et al. A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4-producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J Clin Invest 1998, 101:2268-2277.
37. Sommer N., Harcourt G.C., Willcox N., Beeson D., Newsom-Davis J. Acetylcholine receptor-reactive T lymphocytes from healthy subjects and myasthenia gravis patients. Neurology 1991, 41:1270-1276.
38. Melms A., Malcherek G., Gern U., Wietholter H., Muller C.A., Schoepfer R., et al. T cells from normal and myasthenic individuals recognize the human acetylcholine receptor: heterogeneity of antigenic sites on the alpha-subunit. Ann Neurol 1992, 31:311-318.
39. Willcox N., Leite M.I., Kadota Y., Jones M., Meager A., Subrahmanyam P., et al. Autoimmunizing mechanisms in thymoma and thymus. Ann N Y Acad Sci 2008, 1132:163-173.
40. Shiono H., Roxanis I., Zhang W., Sims G.P., Meager A., Jacobson L.W., et al. Scenarios for autoimmunization of T and B cells in myasthenia gravis. Ann N Y Acad Sci 2003, 998:237-256.
41. Aschenbrenner K., D'Cruz L.M., Vollmann E.H., Hinterberger M., Emmerich J., Swee L.K., et al. Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat Immunol 2007, 8:351-358.
42. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
43. Miyara M., Gorochov G., Ehrenstein M., Musset L., Sakaguchi S., Amoura Z. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011, 10(12):744-755.
44. Balandina A., Lecart S., Dartevelle P., Saoudi A., Berrih-Aknin S. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005, 105:735-741.
45. Masuda M., Matsumoto M., Tanaka S., Nakajima K., Yamada N., Ido N., et al. Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients. J Neuroimmunol 2010, 225:123-131.
46. Luther C., Adamopoulou E., Stoeckle C., Brucklacher-Waldert V., Rosenkranz D., Stoltze L., et al. Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients. J Immunol 2009, 183:841-848.
47. Rowin J., Thiruppathi M., Arhebamen E., Sheng J., Prabhakar B.S., Meriggioli M.N. Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve 2012, 46:449-453.
48. Sheng J.R., Li L.C., Ganesh B.B., Prabhakar B.S., Meriggioli M.N. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. Clin Immunol 2008, 128:172-180.
49. Strobel P., Rosenwald A., Beyersdorf N., Kerkau T., Elert O., Murumagi A., et al. Selective loss of regulatory T cells in thymomas. Ann Neurol 2004, 56:901-904.
50. Luther C., Poeschel S., Varga M., Melms A., Tolosa E. Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma. J Neuroimmunol 2005, 164:124-128.
51. Fattorossi A., Battaglia A., Buzzonetti A., Minicuci G., Riso R., Peri L., et al. Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy. J Clin Immunol 2008, 28:194-206.
52. Strobel P., Helmreich M., Menioudakis G., Lewin S.R., Rudiger T., Bauer A., et al. Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. Blood 2002, 100:159-166.
53. Liu R., Hao J., Dayao C.S., Shi F.D., Campagnolo D.I. T-bet deficiency decreases susceptibility to experimental myasthenia gravis. Exp Neurol 2009, 220:366-373.
54. Sheng J.R., Muthusamy T., Prabhakar B.S., Meriggioli M.N. GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis. J Neuroimmunol 2011, 240-241:65-73.
55. Strobel P., Murumagi A., Klein R., Luster M., Lahti M., Krohn K., et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol 2007, 211:563-571.
56. Scarpino S., Di Napoli A., Stoppacciaro A., Antonelli M., Pilozzi E., Chiarle R., et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol 2007, 149:504-512.
57. Kekalainen E., Tuovinen H., Joensuu J., Gylling M., Franssila R., Pontynen N., et al. A defect of regulatory T cells in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Immunol 2007, 178:1208-1215.
58. Laakso S.M., Laurinolli T.T., Rossi L.H., Lehtoviita A., Sairanen H., Perheentupa J., et al. Regulatory T cell defect in APECED patients is associated with loss of naive FOXP3(+) precursors and impaired activated population. J Autoimmun 2010, 35:351-357.
59. Aricha R., Feferman T., Scott H.S., Souroujon M.C., Berrih-Aknin S., Fuchs S. The susceptibility of Aire(-/-) mice to experimental myasthenia gravis involves alterations in regulatory T cells. J Autoimmun 2011, 36:16-24.
60. Kisand K., Lilic D., Casanova J.L., Peterson P., Meager A., Willcox N. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur J Immunol 2011, 41:1517-1527.
61. Bucknall R.C., Dixon A.S.J., Glick E.N., Woodland J., Zutshi D.W. Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis. Br Med J 1975, 1:600-602.
62. Cavalcante P., Cufi P., Mantegazza R., Berrih-Aknin S., Bernasconi P., Le Panse R. Etiology of myasthenia gravis: Innate immunity signature in pathological thymus. Autoimmun Rev 2013, 12:863-874. (this issue).
63. Weigert C. Pathologisch-anatomischer Beitrag zur Erb'schen Krankheit (myasthenia gravis). Neurol Zentralbl 1901, 20:597-601.
64. Sims G.P., Shiono H., Willcox N., Stott D.I. Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol 2001, 167:1935-1944.
65. Meinl E., Klinkert W.E., Wekerle H. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat. Am J Pathol 1991, 139:995-1008.
66. Wekerle H., Ketelsen U.P. Intrathymic pathogenesis and dual genetic control of myasthenia gravis. Lancet 1977, 1:678-680.
67. Wekerle T.H., Paterson B., Ketelsen U., Feldman M. Striated muscle fibres differentiate in monolayer cultures of adult thymus reticulum. Nature 1975, 256:493-494.
68. Kao I., Drachman D.B. Thymic muscle cells bear acetylcholine receptors: possible relation to myasthenia gravis. Science 1977, 195:74-75.
69. Roxanis I., Micklem K., McConville J., Newsom-Davis J., Willcox N. Thymic myoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis. J Neuroimmunol 2002, 125:185-197.
70. Weinberg C.B., Hall Z.W. Antibodies from patients with myasthenia gravis recognize determinants unique to extrajunctional acetylcholine receptors. Proc Natl Acad Sci U S A 1979, 76:504-508.
71. Kirchner T., Schalke B., Melms A., von Kugelgen T., Muller-Hermelink H.K. Immunohistological patterns of non-neoplastic changes in the thymus in Myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol 1986, 52:237-257.
72. Vincent A., Scadding G.K., Thomas H.C., Newsom-Davis J. In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis. Lancet 1978, 1:305-307.
73. Abdou N.I., Lisak R.P., Zweiman B., Abrahamsohn I., Penn A.S. The thymus in myasthenia gravis. Evidence for altered cell populations. N Engl J Med 1974, 291:1271-1275.
74. Willcox H.N., Newsom-Davis J., Calder L.R. Cell types required for anti-acetylcholine receptor antibody synthesis by cultured thymocytes and blood lymphocytes in myasthenia gravis. Clin Exp Immunol 1984, 58:97-106.
75. Gomez A.M., Vrolix K., Martinez-Martinez P., Molenaar P.C., Phernambucq M., van der Esch E., et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol 2011, 186:2503-2513.
76. Roxanis I., Micklem K., Willcox N. True epithelial hyperplasia in the thymus of early-onset myasthenia gravis patients: implications for immunopathogenesis. J Neuroimmunol 2001, 112:163-173.
77. Wakkach A., Guyon T., Bruand C., Tzartos S., Cohen-Kaminsky S., Berrih-Aknin S. Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis. J Immunol 1996, 157:3752-3760.
78. Willcox N., Schluep M., Ritter M.A., Schuurman H.J., Newsom-Davis J., Christensson B. Myasthenic and nonmyasthenic thymoma. An expansion of a minor cortical epithelial cell subset?. Am J Pathol 1987, 127:447-460.
79. Meraouna A., Cizeron-Clairac G., Panse R.L., Bismuth J., Truffault F., Tallaksen C., et al. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 2006, 108:432-440.
80. Berrih-Aknin S., Ruhlmann N., Bismuth J., Cizeron-Clairac G., Zelman E., Shachar I., et al. CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia. Ann Neurol 2009, 66:521-531.
81. Weiss J.M., Cufi P., Bismuth J., Eymard B., Fadel E., Berrih-Aknin S., et al. SDF-1/CXCL12 recruits B cells and antigen-presenting cells to the thymus of autoimmune myasthenia gravis patients. Immunobiology 2013, 218(3):373-381.
82. Thangarajh M., Masterman T., Helgeland L., Rot U., Jonsson M.V., Eide G.E., et al. The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis. J Neuroimmunol 2006, 178:161-166.
83. Bernasconi P., Barberis M., Baggi F., Passerini L., Cannone M., Arnoldi E., et al. Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. Am J Pathol 2005, 167:129-139.
84. Berrih-Aknin S., Ragheb S., le Panse R., Lisak R.P. Ectopic germinal centers, BAFF and anti-B cell therapy in myasthenia gravis. Autoimmun Rev 2013, 12:885-893. (this issue).
85. Safar D., Aime C., Cohen-Kaminsky S., Berrih-Aknin S. Antibodies to thymic epithelial cells in myasthenia gravis. J Neuroimmunol 1991, 35:101-110.
86. Maniaol A.H., Elsais A., Lorentzen A.R., Owe J.F., Viken M.K., Saether H., et al. Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS One 2012, 7:e36603.
87. Thiruppathi M., Rowin J., Ganesh B., Sheng J.R., Prabhakar B.S., Meriggioli M.N. Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis. Clin Immunol 2012, 145:209-223.
88. Marx A., Wilisch A., Schultz A., Gattenlohner S., Nenninger R., Muller-Hermelink H.K. Pathogenesis of myasthenia gravis. Virchows Arch 1997, 430:355-364.
89. Kisand K., Boe Wolff A.S., Podkrajsek K.T., Tserel L., Link M., Kisand K.V., et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010, 207:299-308.
90. Holbro A., Jauch A., Lardinois D., Tzankov A., Dirnhofer S., Hess C. High prevalence of infections and autoimmunity in patients with thymoma. Hum Immunol 2012, 73:287-290.
91. Saka E., Topcuoglu M.A., Akkaya B., Galati A., Onal M.Z., Vincent A. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005, 65:782-783. [author reply -3].
92. Maggi L., Andreetta F., Antozzi C., Confalonieri P., Cornelio F., Scaioli V., et al. Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor. Neuromuscul Disord 2008, 18:678-680.
93. Rigamonti A., Lauria G., Piamarta F., Fiumani A., Agostoni E. Thymoma-associated myasthenia gravis without acetylcholine receptor antibodies. J Neurol Sci 2011, 302:112-113.
94. Graus F., Dalmau J. Paraneoplastic neurological syndromes. Curr Opin Neurol 2012, 25(6):795-801.
95. Müller-Hermelink H.K., Engel P., Kuo T.T., Ströbel P., Marx A., Harris N.L., et al. Tumours of the thymus. World Health Organization Classification of Tumours: Pathology and Genetics Tumours of the Lung, Pleura, Thymus and Heart 2004, W.D. Travis, E. Brambilla, H.K. Müller-Hermelink, C.C. Harris (Eds.).
96. Hoffacker V., Schultz A., Tiesinga J.J., Gold R., Schalke B., Nix W., et al. Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood 2000, 96:3872-3879.
97. Buckley C., Douek D., Newsom-Davis J., Vincent A., Willcox N. Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann Neurol 2001, 50:64-72.
98. Strobel P., Bauer A., Puppe B., Kraushaar T., Krein A., Toyka K., et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 2004, 22:1501-1509.
99. Kyewski B., Peterson P. Aire, master of many trades. Cell 2010, 140:24-26.
100. Williams C.L., Hay J.E., Huiatt T.W., Lennon V.A. Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin. Lab Invest 1992, 66:331-336.
101. Dardenne M., Savino W., Bach J.F. Thymomatous epithelial cells and skeletal muscle share a common epitope defined by a monoclonal antibody. Am J Pathol 1987, 126:194-198.
102. Marx A., Wilisch A., Schultz A., Greiner A., Magi B., Pallini V., et al. Expression of neurofilaments and of a titin epitope in thymic epithelial tumors. Implications for the pathogenesis of myasthenia gravis. Am J Pathol 1996, 148:1839-1850.
103. Romi F., Bo L., Skeie G.O., Myking A., Aarli J.A., Gilhus N.E. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol 2002, 128:82-89.
104. Kirchner T., Hoppe F., Muller-Hermelink H.K., Schalke B., Tzartos S. Acetylcholine receptor epitopes on epithelial cells of thymoma in myasthenia gravis. Lancet 1987, 1:218.
105. Savino W., Manganella G., Verley J.M., Wolff A., Berrih S., Levasseur P., et al. Thymoma epithelial cells secrete thymic hormone but do not express class II antigens of the major histocompatibility complex. J Clin Invest 1985, 76:1140-1146.
106. Strobel P., Chuang W.Y., Chuvpilo S., Zettl A., Katzenberger T., Kalbacher H., et al. Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. Ann N Y Acad Sci 2008, 1132:143-156.
107. Romi F., Skeie G.O., Gilhus N.E., Aarli J.A. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 2005, 62:442-446.
108. Romi F. Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmun Dis 2011, 2011:474512.
109. Aarli J.A., Stefansson K., Marton L.S., Wollmann R.L. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 1990, 82:284-288.
110. Buckley C., Newsom-Davis J., Willcox N., Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?. Neurology 2001, 57:1579-1582.
111. Meager A., Wadhwa M., Dilger P., Bird C., Thorpe R., Newsom-Davis J., et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 2003, 132:128-136.
112. Cheng M.H., Fan U., Grewal N., Barnes M., Mehta A., Taylor S., et al. Acquired autoimmune polyglandular syndrome, thymoma, and an AIRE defect. N Engl J Med 2010, 362:764-766.
113. Shiono H., Wong Y.L., Matthews I., Liu J.L., Zhang W., Sims G., et al. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int Immunol 2003, 15:903-913.
114. Zettl A., Strobel P., Wagner K., Katzenberger T., Ott G., Rosenwald A., et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000, 157:257-266.
115. Fukui Y., Ishimoto T., Utsuyama M., Gyotoku T., Koga T., Nakao K., et al. Positive and negative CD4+ thymocyte selection by a single MHC class II/peptide ligand affected by its expression level in the thymus. Immunity 1997, 6:401-410.
116. Vandiedonck C., Raffoux C., Eymard B., Tranchant C., Dulmet E., Krumeich S., et al. Association of HLA-A in autoimmune myasthenia gravis with thymoma. J Neuroimmunol 2009, 210:120-123.
117. Gianchecchi E., Palombi M., Fierabracci A. The putative role of the C1858T polymorphism of protein tyrosine phosphatase PTPN22 gene in autoimmunity. Autoimmun Rev Dec 20 2012, [pii: S1568-9972(12)00294-7. [Epub ahead of print]]. 10.1016/j.autrev.2012.12.003.
118. Vandiedonck C., Capdevielle C., Giraud M., Krumeich S., Jais J.P., Eymard B., et al. Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann Neurol 2006, 59:404-407.
119. Chuang W.Y., Strobel P., Gold R., Nix W., Schalke B., Kiefer R., et al. A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol 2005, 58:644-648.
120. Chuang W.Y., Strobel P., Belharazem D., Rieckmann P., Toyka K.V., Nix W., et al. The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. Genes Immun 2009, 10:667-672.
121. Zivkovic S.A., Clemens P.R., Lacomis D. Characteristics of late-onset myasthenia gravis. J Neurol 2012, 259:2167-2171.
122. Romi F., Aarli J.A., Gilhus N.E. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol 2007, 14:617-620.
123. Aarli J.A. Myasthenia gravis in the elderly: is it different?. Ann N Y Acad Sci 2008, 1132:238-243.
124. Aarli J.A., Romi F., Skeie G.O., Gilhus N.E. Myasthenia gravis in individuals over 40. Ann N Y Acad Sci 2003, 998:424-431.
125. Romi F., Gilhus N.E., Varhaug J.E., Myking A., Skeie G.O., Aarli J.A. Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis. Eur J Neurol 2002, 9:55-61.
126. Pedersen E.G., Hallas J., Hansen K., Jensen P.E., Gaist D. Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996-2009. Eur J Neurol 2013, 20(2):309-314.
127. Douek D.C., McFarland R.D., Keiser P.H., Gage E.A., Massey J.M., Haynes B.F., et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998, 396:690-695.
128. Strobel P., Moritz R., Leite M.I., Willcox N., Chuang W.Y., Gold R., et al. The ageing and myasthenic thymus: a morphometric study validating a standard procedure in the histological workup of thymic specimens. J Neuroimmunol 2008, 201-202:64-73.
129. Van de Velde R.L., Friedman N.B. Thymic myoid cells and myasthenia gravis. Am J Pathol 1970, 59:347-368.
130. Giraud M., Beaurain G., Yamamoto A.M., Eymard B., Tranchant C., Gajdos P., et al. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology 2001, 57:1555-1560.
131. Hapnes L., Willcox N., Oftedal B.E., Owe J.F., Gilhus N.E., Meager A., et al. Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups. J Clin Immunol 2012, 32:230-237.
132. Meloni A., Furcas M., Cetani F., Marcocci C., Falorni A., Perniola R., et al. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metabol 2008, 93:4389-4397.
133. Tackenberg B., Schlegel K., Happel M., Eienbroker C., Gellert K., Oertel W.H., et al. Expanded TCR Vbeta subsets of CD8(+) T-cells in late-onset myasthenia gravis: novel parallels with thymoma patients. J Neuroimmunol 2009, 216:85-91.
134. Tackenberg B., Nitschke M., Willcox N., Ziegler A., Nessler S., Schumm F., et al. CD45 isoform expression in autoimmune myasthenia gravis. Autoimmunity 2003, 36:117-121.
135. Alseth E.H., Nakkestad H.L., Aarseth J., Gilhus N.E., Skeie G.O. Interleukin-10 promoter polymorphisms in myasthenia gravis. J Neuroimmunol 2009, 210:63-66.
136. Machens A., Loliger C., Pichlmeier U., Emskotter T., Busch C., Izbicki J.R. Correlation of thymic pathology with HLA in myasthenia gravis. Clin Immunol 1999, 91:296-301.
137. Saruhan-Direskeneli G., Kilic A., Parman Y., Serdaroglu P., Deymeer F. HLA-DQ polymorphism in Turkish patients with myasthenia gravis. Hum Immunol 2006, 67:352-358.
138. Testi M., Terracciano C., Guagnano A., Testa G., Marfia G.A., Pompeo E., et al. Association of HLA-DQB1 *05:02 and DRB1 *16 Alleles with Late-Onset, Nonthymomatous, AChR-Ab-Positive Myasthenia Gravis. Autoimmun Dis 2012, 2012:541760.
139. Mori S., Shigemoto K. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis. Autoimmun Rev 2013, 12:912-917. (this issue).
140. Corda D., Deiana G.A., Mulargia M., Pirastru M.I., Serra M., Piluzza M.G., et al. Familial autoimmune MuSK positive myasthenia gravis. J Neurol 2011, 258:1559-1560.
141. Guptill J.T., Sanders D.B. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 2010, 23:530-535.
142. Lauriola L., Ranelletti F., Maggiano N., Guerriero M., Punzi C., Marsili F., et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005, 64:536-538.
143. Leite M.I., Strobel P., Jones M., Micklem K., Moritz R., Gold R., et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005, 57:444-448.
144. Oshima M., Deitiker P.R., Smith R.G., Mosier D., Atassi M.Z. T-cell recognition of acetylcholine receptor provides a reliable means for monitoring autoimmunity to acetylcholine receptor in antibody-negative myasthenia gravis patients. Autoimmunity 2012, 45:153-160.
145. Khosroshahi A., Bloch D.B., Deshpande V., Stone J.H. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010, 62:1755-1762.
146. Fierabracci A. Recent insights into the role and molecular mechanisms of the autoimmune regulator (AIRE) gene in autoimmunity. Autoimmun Rev 2011, 10(12):744-755.
147. Greve B., Hoffmann P., Illes Z., Rozsa C., Berger K., Weissert R., et al. The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis. Hum Immunol 2009, 70:540-542.